A patient with chronic hepatitis B and regression of fibrosis during treatment

Seminars in Liver Disease

Volumn 30, Issue 3, 2010, Pages 296-301

  Chang, Charissa Y ^a   Martin, Paul ^b   Fotiadu, Anastasia ^c   Hytiroglou, Prodromos ^c  

^a MOUNT SINAI MEDICAL CENTER   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^c ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

Chronic hepatitis B; HBsAg seroconversion; regression of fibrosis

Indexed keywords

ADEFOVIR DIPIVOXIL; ALPHA INTERFERON; ENTECAVIR; HEPATITIS B SURFACE ANTIGEN; LAMIVUDINE;

ADULT; ANTIVIRAL THERAPY; CASE REPORT; CHRONIC HEPATITIS; DISEASE ACTIVITY; HEPATITIS B; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LIVER BIOPSY; LIVER FIBROSIS; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REMISSION; REVIEW; SEROCONVERSION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANTIVIRAL AGENTS; BIOPSY; DNA, VIRAL; DRUG ADMINISTRATION SCHEDULE; HEPATITIS B ANTIBODIES; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; TIME FACTORS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 77954968875     PISSN: 02728087     EISSN: 10988971     Source Type: Journal    
DOI: 10.1055/s-0030-1262515     Document Type: Review

References (35)

1. Ishak K, Baptista A, Bianchi L et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995 22 (6) 696-699
2. Poynard T, McHutchison J, Manns M et al. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 2002 122 (5) 1303-1313
3. Dienstag J L., Goldin R D., Heathcote E J. et al. Histological outcome during long-term lamivudine therapy. Gastroenterology 2003 124 (1) 105-117
4. Czaja A J., Carpenter H A. Decreased fibrosis during corticosteroid therapy of autoimmune hepatitis. J Hepatol 2004 40 (4) 646-652
5. Dixon J B., Bhathal P S., Hughes N R., O'Brien P E. Nonalcoholic fatty liver disease: Improvement in liver histological analysis with weight loss. Hepatology 2004 39 (6) 1647-1654
6. Falize L, Guillygomarc'h A, Perrin M et al. Reversibility of hepatic fibrosis in treated genetic hemochromatosis: a study of 36 cases. Hepatology 2006 44 (2) 472-477
7. Chang T T., Gish R G., de Man R et al, BEHoLD AI463022 Study Group. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006 354 (10) 1001-1010
8. Lai C L., Shouval D, Lok A S. et al, BEHoLD AI463027 Study Group. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006 354 (10) 1011-1020
9. Hadziyannis S J., Tassopoulos N C., Heathcote E J. et al, Adefovir Dipivoxil 438 Study Group. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 2006 131 (6) 1743-1751
10. Marcellin P, Heathcote E J., Buti M et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med 2008 359 (23) 2442-2455
11. Schiff E, Simsek H, Lee W M. et al. Efficacy and safety of entecavir in patients with chronic hepatitis B and advanced hepatic fibrosis or cirrhosis. Am J Gastroenterol 2008 103 (11) 2776-2783
12. Moucari R, Korevaar A, Lada O et al. High rates of HBsAg seroconversion in HBeAg-positive chronic hepatitis B patients responding to interferon: a long-term follow-up study. J Hepatol 2009 50 (6) 1084-1092
13. Wanless I R., Nakashima E, Sherman M. Regression of human cirrhosis. Morphologic features and the genesis of incomplete septal cirrhosis. Arch Pathol Lab Med 2000 124 (11) 1599-1607
14. Malekzadeh R, Mohamadnejad M, Rakhshani N et al. Reversibility of cirrhosis in chronic hepatitis B. Clin Gastroenterol Hepatol 2004 2 (4) 344-347
15. Bortolotti F, Guido M, Cadrobbi P et al. Spontaneous regression of hepatitis B virus-associated cirrhosis developed in childhood. Dig Liver Dis 2005 37 (12) 964-967
16. Serpaggi J, Carnot F, Nalpas B et al. Direct and indirect evidence for the reversibility of cirrhosis. Hum Pathol 2006 37 (12) 1519-1526
17. Friedman S L. Mechanisms of hepatic fibrogenesis. Gastroenterology 2008 134 (6) 1655-1669
18. Jiao J, Friedman S L., Aloman C. Hepatic fibrosis. Curr Opin Gastroenterol 2009 25 (3) 223-229
19. Anthony P P., Ishak K G., Nayak N C., Poulsen H E., Scheuer P J., Sobin L H. The morphology of cirrhosis: definition, nomenclature, and classification. Bull World Health Organ 1977 55 (4) 521-540
20. Wanless I R. Vascular disorders In: Burt AD, Portmann BC, Ferrell LD MacSween's Pathology of the Liver. 5th ed. Philadelphia Churchill Livingstone 2007 613-648
21. Nakashima E, Kage M, Wanless I R. Idiopathic portal hypertension: histologic evidence that some cases may be regressed cirrhosis with portal vein thrombosis. Hepatology 1999 30 218A
22. Scheuer P J. Classification of chronic viral hepatitis: a need for reassessment. J Hepatol 1991 13 (3) 372-374
23. Bedossa P, Poynard T, The METAVIR Cooperative Study Group. An algorithm for the grading of activity in chronic hepatitis C. Hepatology 1996 24 (2) 289-293
24. Hytiroglou P, Thung S N., Gerber M A. Histological classification and quantitation of the severity of chronic hepatitis: keep it simple! Semin Liver Dis 1995 15 (4) 414-421
25. Afdhal N H., Nunes D. Evaluation of liver fibrosis: a concise review. Am J Gastroenterol 2004 99 (6) 1160-1174
26. Sorrell M F., Belongia E A., Costa J et al. National Institutes of Health consensus development conference statement: management of hepatitis B. Hepatology 2009 49 (5, Suppl) S4-S12
27. Feld J J., Wong D KH, Heathcote E J. Endpoints of therapy in chronic hepatitis B. Hepatology 2009 49 (5, Suppl) S96-S102
28. Huo T I., Wu J C., Lee P C. et al. Sero-clearance of hepatitis B surface antigen in chronic carriers does not necessarily imply a good prognosis. Hepatology 1998 28 (1) 231-236
29. Chen Y C., Sheen I S., Chu C M., Liaw Y F. Prognosis following spontaneous HBsAg seroclearance in chronic hepatitis B patients with or without concurrent infection. Gastroenterology 2002 123 (4) 1084-1089
30. Yuen M F., Wong D K., Fung J et al. HBsAg Seroclearance in chronic hepatitis B in Asian patients: replicative level and risk of hepatocellular carcinoma. Gastroenterology 2008 135 (4) 1192-1199
31. Liaw Y F., Sheen I S., Chen T J., Chu C M., Pao C C. Incidence, determinants and significance of delayed clearance of serum HBsAg in chronic hepatitis B virus infection: a prospective study. Hepatology 1991 13 (4) 627-631
32. McMahon B J. The natural history of chronic hepatitis B virus infection. Hepatology 2009 49 (5, Suppl) S45-S55
33. Lampertico P, Del Ninno E, Vigan M et al. Long-term suppression of hepatitis B e antigen-negative chronic hepatitis B by 24-month interferon therapy. Hepatology 2003 37 (4) 756-763 (Pubitemid 36397385)
34. Marcellin P, Lau G KK, Bonino F et al, Peginterferon Alfa-2a HBeAg-Negative Chronic Hepatitis B Study Group. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2004 351 (12) 1206-1217
35. Hadziyannis S, Sevastianos V, Rapti I. Outcome of HBeAg-negative chronic hepatitis B 5 years after discontinuation of long term adefovir dipivoxil treatment. J Hepatol 2009 50 (Suppl 1) S9